Overview

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic heart failure (DHF), and that the improvements in exercise tolerance will correlate with the improvements in aortic distensibility.
Phase:
Phase 2
Details
Lead Sponsor:
Synvista Therapeutics, Inc